



BWX Technologies, Inc.

BWXT

EQUITY RESEARCH REPORT

September 24, 2026

BWXT — BWX Technologies, Inc.

Report Date: 2026-09-24

Analyst: Moschovakis Capital Research

EXECUTIVE SUMMARY

Metric	Value
Recommendation	**HOLD / WATCHLIST**
Current Price	\$140.51 / €123.56
Fair Value (Base Case)	\$138.00 / €121.30
Margin of Safety	-1.8% (slightly above fair)
Target Entry (for HOLD)	\$124.00 / €109.00

Return Profile	Value
Dividend Yield	~0.8% (not in supplied data; flagged estimate)
Expected Dividend Growth	~5% (immaterial to total return)
Expected Price Appreciation (Base)	~8.1% CAGR
Total Expected Return (Base)	~8.9% CAGR
Bear Case Total Return	~2.0% CAGR
Bull Case Total Return	~13.5% CAGR
Probability-Weighted Return	~8.4% CAGR

Risk Assessment	Value
Wealth Preservation Score	64 / 100
Downside Protection Score	65 / 100
Quality Score	54 / 100
Risk Level	MODERATE
Probability of >50% Loss	<8%
Recession Profile	RESILIENT (core) / SENSITIVE (overall)

One-Line Thesis:

BWXT owns a government-sanctioned monopoly on U.S. Navy nuclear reactor supply with a \$8.65B backlog, positive and rising free cash flow, and a post-selloff forward multiple near its five-year average, but at \$140.51 it

offers no margin of safety for a wealth-preservation mandate, so the disciplined action is to wait for a 10% discount rather than pay up for quality.

INVESTMENT THESIS

BWX Technologies is the sole supplier of nuclear reactors and fuel for the U.S. Navy's submarine and aircraft carrier fleets. This position is the economic heart of the business. The Navy cannot switch vendors on a whim; qualified-supplier status for naval nuclear propulsion requires decades of clearances, certifications, and program history. Koalagains describes it as a government-sanctioned monopoly, and the structural evidence supports that framing. Government Operations carries roughly 70% of consolidated revenue with segment EBITDA margins near 19.2% in Q3 2025. This segment produces a recurring, defense-funded revenue stream that does not depend on discretionary consumer spending or commodity prices.

The second leg is Commercial Operations, which includes commercial nuclear components, field services, medical radioisotopes, and the emerging microreactor and TRISO fuel businesses. This segment delivered \$283.6M in Q1 2026 revenue, up 121% year over year, and the medical unit alone crossed \$100M. The December 2025 Kozloduy AP1000 owner's engineer contract in Bulgaria marks BWXT's first meaningful AP1000 award. The U.S. Army's August 2026 selection of BWXT's BANR microreactor for the Janus program at Fort Campbell validates the advanced nuclear thesis. These commercial projects give BWXT optionality beyond the Navy, but they remain second-order contributors next to the defense anchor.

The valuation has de-rated sharply. The stock traded near \$216 in May 2026 and now sits at \$140.51, a 35% decline that brings the forward multiple to roughly 30x on fiscal 2026 earnings guidance of \$4.55 to \$4.70 per share. That multiple sits near the five-year average rather than far above it. The base-case arithmetic produces a total return near 9% per year: roughly 8% from earnings growth of about 9% per year, plus a token dividend near 0.8%. That clears the 7% hurdle the mandate sets against a 4% savings account. The bear case, modeled at 4% earnings growth and a 22x terminal multiple, still leaves the price about \$150 in ten years, a positive but thin 2% annual return including dividends.

The problem for a capital-preservation mandate is the entry price. A stock can be a wonderful business and a mediocre investment if you pay the wrong price. BWXT is a wonderful business. At \$140.51 it is a mediocre entry. The fair-value midpoint, using a 28x to 30x multiple on fiscal 2026 earnings of \$4.62, lands around \$129 to \$139. Current price sits at the top of that band, offering no cushion. The framework's absolute requirement for a BUY is a bear case that preserves capital, which BWXT passes, plus a base case above 7%, which it passes, plus a margin of safety of at least 10%, which it fails.

The disciplined outcome is a HOLD with a defined entry target. At \$124, roughly 12% below current, the margin of safety to the \$138 fair value exceeds 10% and the forward multiple compresses to about 27x, which restores the asymmetry the mandate demands. Paying \$140.51 for a business this good is not reckless. It is simply not consistent with the rule that you first ask how much you can lose. You can lose 20% to 30% if the multiple compresses toward the sector median even as the underlying business keeps growing. The right response is patience.

Cash in a 4% savings account competes with BWXT at this price. The savings account gives you 4% with essentially zero drawdown. BWXT offers perhaps 9% with a realistic 25% near-term drawdown scenario. That spread is positive but not overwhelming. A better entry raises the expected return toward 10% or 11% and cuts the drawdown risk by a third. Wait for that number.

1. BUSINESS QUALITY ASSESSMENT

BWXT manufactures precision naval nuclear components, reactors, and fuel for the U.S. Government, and sells nuclear materials processing, environmental site restoration, medical radioisotopes, and commercial nuclear services. The 10-K filed February 23, 2026 describes a business operating in capital-intensive industries where a small number of projects can represent a large share of operations. That project concentration is real, but the anchor project base, the Navy, does not behave like a typical customer.

The two reportable segments split into Government Operations and Commercial Operations. Government Operations carries approximately 70% of revenue and posts segment EBITDA margins near 19.2%. This segment holds the qualification moat. Naval nuclear certification demands a chain of security clearances, facility certifications, and process validations that no competitor can shortcut. Umbrex notes the defense-like demand visibility and very long program lives. Koalagains frames the position as a government-sanctioned monopoly where the Navy cannot switch away because qualified-supplier status locks in decades of work. The \$8.65B backlog, roughly 2.6x annual revenue, gives exceptional visibility. Fiscal 2025 bookings surged 51% to \$5.36B, which means the backlog is being replenished faster than it is consumed.

Commercial Operations adds growth but also adds cyclical. Q1 2026 commercial revenue of \$283.6M, up 121% from \$128.3M a year earlier, came from commercial nuclear components, field services, and medical sales. The medical radioisotope unit passed \$100M in annualized revenue. The Bulgaria Kozloduy AP1000 contract and the Army Janus microreactor selection extend the commercial runway. These are real, but they depend on utility capital budgets and medical procurement cycles, which are not as stable as Navy appropriations.

Competitors include General Electric, Westinghouse, Northrop Grumman, Framatome, and Rolls, plus next-generation reactor startups NuScale, X-energy, and TerraPower. None of the primes can displace BWXT in naval propulsion without a decade of qualification work. The startups compete in the commercial advanced reactor space, not in the Navy program. BWXT's patents in reactor design, fuel fabrication, and nuclear materials processing bolster the moat. Research and development spending is modest relative to some peers, and fiscal 2025 capex of approximately \$193M, about 6% of revenue, went heavily toward manufacturing facility expansion rather than pure R&D. That matters: BWXT is investing in capacity to meet backlog, not in speculative research to defend a weakening position. The moat does not require defense spending to grow; it requires the Navy to keep sailing its fleet, which the strategic environment makes likely for decades.

The durability question is the one that matters for preservation. Can this competitive position erode materially in ten years? The Navy has no alternative supplier. The revenue anchor is funding that survives recessions because submarines and carriers are decade-long capital programs, not annual discretionary items. The commercial segment could falter in a downturn, but at 30% of revenue a commercial downturn dents growth, it does not imperil the enterprise. The moat is wide on durability and narrow on breadth. Quality is exceptional for the core; the preservation judgment depends on whether the price respects that quality.

2. FINANCIAL FORTRESS ANALYSIS

The balance sheet is the weakest link in an otherwise strong preservation case. Trefis data from September 10, 2026 shows \$2.0B in debt against \$0.6B in cash, for net debt of \$1.4B. The implied book value, using the

reported price-to-book of 13.31x against a \$140 price, is roughly \$965M. That places debt-to-equity near 2.0x, well above the framework's 1.0x threshold and far above the 0.5x fortress level. For a wealth-preservation mandate, this is the single largest quantitative red flag.

Interest coverage tells a more forgiving story. Fiscal 2026 adjusted EBITDA guidance of \$645M to \$660M implies coverage of roughly seven to eight times estimated interest expense, which is acceptable though not spectacular. The company generates consistent free cash flow: \$212M in 2023, \$285M in fiscal 2025, and a guided \$305M to \$320M in 2026. Free cash flow has covered net income at roughly 86% in both 2023 and 2025, which confirms earnings quality rather than accounting shell games. There are no restatements, no auditor warnings, and no going-concern language in the supplied filings.

The stress test matters more than the static ratios. If revenue fell 30% for two years, a severe but plausible defense-adjacent scenario, the model works this way. Fiscal 2026 revenue of \$3.75B contracts to about \$2.6B. At BWXT's operating margin near 10%, operating profit falls from roughly \$375M to perhaps \$260M, and adjusted EBITDA compresses from the mid-\$600M range toward \$450M. Interest expense near \$90M remains comfortably covered five times over. The dividend, which is token relative to earnings, survives without stress. Free cash flow thins but stays positive because the heavy capex program is discretionary. The company could defer growth capex in a downturn and protect the balance sheet.

The structural concern is the convertible senior notes due 2030, flagged in SEC records with related subsidiary guarantees. The supplied data does not provide conversion terms, principal amount, or covenant specifics. This is a monitoring item, not an immediate disqualifier. A conversion could add dilution; a refinancing at maturity in 2030 could reset interest costs. Neither threatens solvency given current cash flow generation, but both reduce the margin for error.

Solvency assessment: ADEQUATE, not FORTRESS. The framework asks whether the company survives a severe recession. BWXT survives easily on the operating side; the Navy pays, the backlog is contractual, and cash flow is positive. The leverage means BWXT does not have the fortress balance sheet the mandate prefers. A preservation investor accepts this only with a valuation discount, and at \$140.51 there is no discount. The balance sheet is strong enough to hold the company; it is not strong enough to justify paying up.

3. DIVIDEND ANALYSIS

The supplied research data contains no dividend figures for BWXT: no yield, no payout ratio, no dividend history, no growth rate, no consecutive-years count. The framework requires the analyst to flag this gap rather than invent numbers. BWXT pays a modest dividend according to general market knowledge, with a yield below 1.5% at the current price. I estimate the yield near 0.8% and label that as an external estimate, not a figure from the provided inputs.

For the wealth-preservation mandate, the dividend is immaterial to the total return. With a payout ratio that is trivially low relative to free cash flow, the dividend carries essentially zero cut risk. The sustainability question does not arise because the payment is so small that coverage is effectively infinite. What matters is what the dividend tells you about the capital allocation story. BWXT returns capital to shareholders through contract-driven earnings growth, not through income distributions. A 0.8% yield does not meaningfully buffer a drawdown, and it does not help the return clear the 7% hurdle; the earnings growth and multiple do that work.

The scoring system penalizes this. The income reliability sub-score receives few points because the framework rewards yield in the 2% to 4% range with a payout below 60% and a long dividend history. BWXT offers a token

yield and a short standalone dividend record. That is a legitimate framework output, not a judgment that the dividend is unsafe. If you require current income to meet the inflation-plus-4% target, this is not your vehicle. A 4% savings account pays five times the yield at a fraction of the risk. The preservation case for BWXT depends on total return, and the total return depends on earnings compounding with the multiple holding steady.

For completeness, the dividend's contribution to the base-case 8.9% total return is roughly 0.8 percentage points, and the remainder is price appreciation from earnings growth. The bear case dividend contribution is similar in magnitude and does not rescue a weak outcome. The dividend is safe, small, and structurally irrelevant. Note the gap: the supplied research does not permit a detailed dividend sustainability analysis, and the mandate's income-reliability scoring should reflect that absence honestly.

4. VALUATION ANALYSIS

The most important valuation fact is the price action that preceded this report. BWXT traded near \$216 in May 2026 according to VCP Scanner data. The stock has since fallen 35% to \$140.51, and Perplexity noted the stock was down over 15% from recent highs and near its 52-week low before this latest leg. A de-rating of that magnitude changes the valuation conversation. The question is no longer whether BWXT deserves a premium multiple; it is whether the remaining premium is justified after the decline.

Trailing earnings tell one story. Net income reached \$329.9M in fiscal 2025, or roughly \$3.61 per share on 91.4M shares. At \$140.51 the trailing P/E is approximately 39x. The five-year average GAAP P/E sits near 33x according to Seeking Alpha. Looked at this way, the stock still trades about 18% above its own history and roughly 45% above the sector median P/E of 20.9x. Peer primes Lockheed Martin, Northrop Grumman, and General Dynamics trade between 16x and 28x.

Forward earnings tell a different, more forgiving story. Fiscal 2026 guidance of \$4.55 to \$4.70 in adjusted EPS, with a midpoint of \$4.62, implies a forward P/E near 30x. The five-year average forward non-GAAP P/E is approximately 29x. BWXT now trades at its own historical forward average, not above it. The premium to sector remains, but it has compressed from the roughly 89% premium cited in earlier snapshots to something closer to 45%. ChartMill shows a forward PEG of 1.82, while VCP Scanner shows a much higher forward PEG of 10.94 at the higher May price. The divergence reflects different growth-rate assumptions and different price bases; both figures carry stale price inputs that predate the current \$140.51.

The absolute multiples remain expensive for a preservation portfolio. EV/EBITDA runs near 25x on trailing EBITDA and approximately 22x on fiscal 2026 guidance. Price-to-free-cash-flow sits near 40x on the guided \$305M to \$320M range. Price-to-book of 13.3x is more than four times the sector median. GuruFocus's GF Value of \$154.33 from September 1 was computed against a \$161.54 price and implied modest overvaluation. Simply Wall St produced a DCF fair value of \$125.56, below both the September 1 price and the current price.

The fair-value midpoint I use is \$129 to \$139, applying a 28x to 30x multiple to fiscal 2026 earnings of \$4.62. This range brackets the five-year average and respects the moat. Current price of \$140.51 sits just above the top of the range, producing a margin of safety of about negative 1.8%. Valuation verdict: FAIR to slightly FULL. The stock is no longer egregiously expensive after a 35% drawdown, but it offers no cushion against disappointment. A preservation investor buys below fair value, not at it.

5. SCENARIO ANALYSIS

The bear case assumes the growth engine decelerates and the market re-rates the multiple toward the defense-sector norm. Fiscal 2026 earnings of \$4.62 grow at only 4% per year for a decade, reaching \$6.84. A budget reprioritization, a Navy procurement pause, or a commercial nuclear slowdown could produce this. The market applies a 22x terminal multiple, down from today's 30x. The ten-year price lands near \$150, roughly flat against the current \$140.51. Adding a token dividend return of roughly eight to ten percentage points cumulative, the bear case total return comes to approximately 2% per year. That is positive, which means capital survives. But the interim path matters. If the multiple compresses quickly to 22x on 2026 earnings, the price dips toward \$102, a 28% drawdown from current before recovering. A preservation investor must be able to hold through that drawdown without capitulating.

The base case assumes BWXT compounds earnings at the consensus pace while the multiple settles to its historical average. Earnings grow 9% per year from \$4.62 to approximately \$10.93 in ten years. A 28x terminal multiple, consistent with the five-year average, prices the stock at \$306. That produces price appreciation of about 8.1% per year and a total return near 8.9% including the dividend. This clears the 7% hurdle with a modest buffer.

The bull case assumes the commercial growth engine inflects and the premium persists. Earnings grow 12% per year to \$14.35 per share. The market pays 32x, reflecting successful microreactor deployment at Fort Campbell, the Kozloduy AP1000 program converting to revenue, and medical isotopes scaling. The ten-year price reaches \$459, a total return near 13.5% per year. This scenario requires the advanced nuclear narrative to convert from backlog announcements to reported margins.

The probability-weighted expected return across these scenarios is approximately 8.4% per year. The weighting of 25% bear, 50% base, and 25% bull reflects the asymmetric judgment that the downside is shallower than the upside but more likely to arrive in the near term. The bear case is positive, which satisfies the framework's absolute requirement. The base case clears the hurdle. The failure is the margin-of-safety test, not the return test.

The decisive question for a preservation mandate is the bear-case path. A 28% interim drawdown with a 2% long-run return is a frustrating experience for a capital-preservation investor. It requires holding through a decline that feels like permanent loss even if it is not. The alternative, a 4% savings account, produces no such drawdown. That comparison is the reason the recommendation is HOLD and not BUY. At a \$124 entry the bear case mathematics shift; the multiple compression to 22x produces a shallower interim decline, the long-run bear return rises toward 4%, and the asymmetry becomes acceptable.

6. RISK ASSESSMENT

Concentration risk is the first and largest exposure. Roughly 70% of revenue comes from U.S. Government contracts, dominated by the Navy. Trefis, GuruFocus, and Fernfortuniversity all flag heavy reliance on government spending as the primary vulnerability. A single customer that is also a sovereign entity creates a unique risk profile. The Navy cannot replace BWXT easily, but the Navy's budget is a political object. A defense spending reallocation, a procurement pause, or a shift in fleet strategy would slow the anchor segment. The \$8.65B backlog cushions against this, but it is not infinite. Renewed awards have become an increasingly critical revenue driver.

Regulatory and environmental liability sits alongside concentration. BWXT operates nuclear facilities with substantial compliance obligations. GuruFocus notes that environmental incidents could produce financial liabilities. The nuclear industry carries tail risk that a standard industrial does not. A serious incident at a BWXT facility would trigger more than litigation; it could threaten the qualified-supplier status that underpins the moat. The probability is low, but the mandate must account for tail risk even when the base case is comfortable.

Valuation risk remains despite the drawdown. A 30x forward multiple against a sector at 21x leaves room for further compression if growth disappoints. Simply Wall St calculated a DCF fair value of \$125.56, and the VCP bear scenario sits at \$160.59 on a higher price base. The stock already absorbed a 35% decline, but a re-rating toward the peer average would take another 25% to 35% off the price. Rising bond yields pressure industrials broadly, and the stock traded near 52-week lows before this report even as fundamental news stayed positive.

Margin risk is developing. Q1 2026 Government Operations revenue grew only 4% year over year against an analyst bar that AskTraders described as double-digit. Simply Wall St noted flat net margins near 10.3% and declining organic revenue in commercial operations, where acquisitions drove segment growth. If the growth engine fails to convert backlog into margin expansion, the multiple loses its justification.

Governance and state-signal risk appear modest. The SEC record shows routine insider transactions such as the August 2025 exercise and sale by Whitford at \$177.43, which is a standard cashless option exercise rather than a sell signal. Simply Wall St mentions recent insider selling without specific detail in the supplied data. ESG Risk Score is 32.5 on the Sustainalytics scale, with a Governance Risk Score of 4.2. The convertible notes due 2030 create a modest dilution overhang.

Mitigation for all of this comes from the structure. The backlog covers 2.6 years of revenue. Free cash flow is positive and rising. The Navy has no substitute supplier. The probability of a greater-than-50% permanent loss appears below 8%, inside the mandate's 10% threshold. The risk is not destruction; it is a multi-year return of disappointment if the multiple normalizes faster than earnings grow.

7. MANAGEMENT & GOVERNANCE

The supplied research does not provide a management quality assessment, compensation detail, or insider ownership percentages. GlobalData's Filings Sentiment of 0.73 and the SEC summary language that the MD&A remains optimistic are the closest available proxies. I must flag this gap and build the governance assessment from filing-index evidence rather than a full management dossier.

The SEC record identifies the leadership structure indirectly. Form 4 filings for Rex D. Geveden appear in February and May 2026, and the prior CEO Gerhard Burbach shows Form 4 activity in December 2025 along with deferred restricted stock units and dividend equivalent rights. A Form 3 for Kurt A. Bender filed February 6, 2026 indicates a new insider, likely the chief financial officer. Whitford serves as senior vice president and general counsel and executed a routine option exercise in August 2025, buying 2,092 shares at \$61.70 and selling the same shares at \$177.43, leaving a meaningful retained position with additional options expiring in 2033. Director Jan Bertsch and a Richardson receive dividend equivalent rights tied to restricted stock units, which indicates equity-linked director compensation.

No management red flags appear in the supplied data. No accounting restatements, no SEC investigations, no auditor warnings, no going-concern language, and no compensation controversies surface in the sources. The Governance Risk Score of 4.2 on Sustainalytics' scale, where lower is better, suggests a clean governance profile relative to industrial peers. The total ESG score of 32.5 reflects environmental and social exposure from

the nuclear business rather than governance failures.

Capital allocation history is incomplete in the inputs. The BHI Energy acquisition in 2022 expanded commercial services, and fiscal 2025 capex of roughly \$193M went toward manufacturing capacity. The convertible notes due 2030 represent a financing decision the supplied data does not detail. No buyback history, dividend growth record, or full M&A history is provided. The capital allocation track record cannot be scored beyond the observable facts: the company reinvests heavily against a record backlog and uses modest leverage.

Management quality verdict: ADEQUATE to GOOD, with an explicit caveat. The operational record of backlog growth, consistent earnings beats, and positive free cash flow supports a competent management team. The absence of detailed compensation and allocation data prevents a stronger endorsement. A preservation investor should monitor the convertible note terms, the pace of acquisitions, and the alignment metrics when the proxy statement details become available.

8. PEER COMPARISON

BWXT does not have a perfect peer. The closest aerospace and defense primes trade at materially lower multiples because they grow slower and lack a monopoly on a single critical program.

Dimension	BWXT	Lockheed Martin	Northrop Grumman	General Dynamics	Curtiss-Wright
Forward P/E	~30x	~18x	~21x	~20x	~25x
Revenue Growth (recent 10% YoY)	~18%	Mid-single digit	Mid-single digit	Mid-single digit	Mid-single digit
Margins (EBITDA)	~17-19% Gov Ops	~14%	~14%	~13%	~18%
Backlog / Revenue	~2.6x	~2x	~2x	~2x	~2x
Balance Sheet Leverage	~2.0x D/E	~1.5x D/E	~1.2x D/E	~0.8x D/E	<1.0x D/E
Dividend Yield	~0.8%	~2.8%	~2.0%	~2.4%	~0.5%
Moat	Sole-source Navy nuclear	Platform breadth	Platform breadth	Platform breadth	Niche defense nuclear

BWXT's valuation premium over the primes rests on growth and monopoly. The company grew revenue 18% in 2024 and 23% on a trailing basis, while the primes manage mid-single-digit growth. BWXT's Government Operations margins of 19.2% exceed the primes. The \$8.65B backlog covers 2.6 times annual revenue, the strongest coverage in the group. The sole-source Navy position has no analog at Lockheed or Northrop, which compete across multiple programs and face periodic contract losses.

The premium is not free. BWXT carries higher leverage than any prime except perhaps Lockheed, pays the lowest yield, and relies on a single customer for the majority of revenue. The primes diversify across the Army, Navy, Air Force, international customers, and commercial aerospace. BWXT's diversification comes from commercial nuclear and medical isotopes, which are smaller and more cyclical than the prime defense franchises.

Curtiss-Wright provides the best defensive-comparison benchmark. It shares the nuclear-defense niche, similar revenue scale near \$2.7-3B, and comparable specialty margins. BWXT trades at a modest premium to Curtiss-Wright on forward earnings, which the faster growth and stronger backlog justify. The comparison that matters for preservation is against the sector median P/E of roughly 21x. BWXT at 30x forward carries roughly

nine multiple points of premium that must be supported by continued double-digit earnings growth. If that growth persists, the premium is earned. If it dips toward single digits, the multiple follows.

9. KEY METRICS SUMMARY

Metric	Value	Source / Period
Revenue (FY2023)	\$2.5B	GuruFocus/Yahoo 8-K
Revenue (TTM)	~\$3.2B	PitchGrade / Simply Wall St
Revenue Guidance (FY2026)	~\$3.75B	MetricDuck Q4 FY2025
Net Income (FY2025)	\$329.9M	SEC 10-K
Net Income (FY2024)	\$282.3M	SEC 10-K
Adjusted EBITDA FY2026E	\$645M - \$660M	Company guidance
EPS FY2026E	\$4.55 - \$4.70	Company guidance
Free Cash Flow FY2026E	\$305M - \$320M	Company guidance
Backlog	\$8.65B	Koalagains
FY2025 Bookings	\$5.36B (+51% YoY)	Koalagains
Debt	\$2.0B	Trefis 9/10/26
Cash	\$0.6B	Trefis 9/10/26
Net Debt	\$1.4B	Trefis 9/10/26
Debt/Equity	~2.0x	Calculated
Interest Coverage	~7-8x	Calculated
FCF / Net Income	~86%	Calculated
Trailing P/E	~39x	Calculated at \$140.51
Forward P/E	~30x	Calculated at \$140.51 / \$4.62
EV/EBITDA (fwd)	~22x	Calculated
P/B	13.3x	Seeking Alpha
P/FCF	~40x	Calculated
5Y Avg Forward P/E	~29x	Seeking Alpha
ROIC	~10%	Calculated
Segment EBITDA Margin (GovOps, Q3 25)	19.2%	AlInvest
Segment EBITDA Margin (Commercial, Q3 25)	15.7%	AlInvest

10. MONITORING CHECKLIST

Item	Cadence	Bull Trigger	Bear Trigger
Backlog	Quarterly	>\$9.0B or bookings growth >20%	<2.0x revenue or two declining booking y
Gov Ops Revenue Growth	Quarterly	>10% YoY	<5% YoY for two quarters
Commercial Revenue Growth	Quarterly	>40% YoY	Negative organic growth
Medical Segment Revenue	Quarterly	>\$30M/quarter run-rate	<\$100M annualized
Gov Ops EBITDA Margin	Quarterly	>20%	<15%
Free Cash Flow	Quarterly	>\$80M/quarter	<\$60M/quarter
Adjusted EPS	Quarterly	Beat consensus >5%	Miss consensus
Net Margin	Quarterly	>11%	<9%
Debt / Net Debt	Semi-annual	Net debt declining	Net debt >\$1.6B
Convertible Notes 2030 Terms	As filed	No dilution	Conversion >2% dilution
Navy Contract Awards	As announced	New multi-year award	Award dispute or delay
Microreactor (Janus) Milestones	As announced	Deployment timetable holds	Cancellation or delay
Insider Transactions	As filed	No unusual sales	Cluster selling at prices <\$160
10-Yr Treasury Yield	Weekly	<4.0%	>4.75%
Investor Day (Sep 29, 2026)	Event	Raises long-term targets	Softens growth outlook

11. MARKET EXPECTATIONS & CONSENSUS

What the current stock price implies about growth:

The market is pricing BWXT as a premium compounder that will sustain high single-digit to low double-digit earnings growth. Consensus earnings expectations from Simply Wall St call for 10.8% annual earnings growth and 8.7% annual revenue growth. At the current \$140.51 price and a 30x forward multiple on \$4.62 of guided 2026 earnings, the implied growth needed to hold the multiple is the consensus rate itself. A company growing earnings near 10% can support a 30x multiple only if the growth persists for years; the market has already shifted from paying 40x to 30x on this prospect, which is the de-rating we have witnessed. The VCP Scanner estimate of 28.7% next-year EPS growth is a one-year view that reflects easy trailing comparisons and guidance raises, not a durable run rate.

Consensus Bull Case:

Analysts framing the bull case cite the near-monopolistic naval position, the record \$8.4B to \$8.65B backlog, the Army Janus microreactor selection, and TRISO fuel strength. Northland reiterated Buy with a \$250 target and BTIG reiterated Buy with a \$235 target. Guggenheim initiated at \$192 and Jefferies at \$181. The bull arithmetic requires earnings reaching roughly \$495M by 2028, a 14.5% CAGR from fiscal 2025's \$330M, which supports a

continued premium multiple. Delivery of the Kozloduy AP1000 owner's engineer contract and the Fort Campbell deployment validates the commercial leg.

Consensus Bear Case:

Wells Fargo upgraded the stock to Equal-Weight from Underweight while cutting its target to \$170, and VCP's bear scenario sits at \$160.59 on a higher price base. Simply Wall St calculates a DCF fair value of \$125.56. The bear narrative points to flat net margins near 10.3%, declining organic commercial revenue where acquisitions drove the reported growth, high debt, recent insider selling, and a P/E that remains above the peer average of 38.8x even after the drawdown. Multiple compression toward the peer average would take the stock materially below \$125.

Short Interest: Not covered in the supplied research. No short interest or days-to-cover data was provided, and I will not fabricate a figure.

Analyst Consensus: The supplied sources report Strong Buy to Buy ratings across 9 to 16 analysts with targets ranging from \$170 to \$255. The average target of \$210 to \$235 was computed at higher price snapshots. At the current \$140.51, the same targets imply meaningful upside, but the framework weighs downside risk before upside. The target dispersion of \$85 between the low and high reflects genuine disagreement about whether the commercial nuclear narrative justifies a premium multiple.

What would validate the consensus: A fiscal third-quarter 2026 earnings beat against the \$1.19 estimate on November 2, 2026; Government Operations revenue accelerating back toward double digits; backlog conversion showing through in reported margins above 11% net; the Investor Day on September 29, 2026 raising long-term targets; and further microreactor or TRISO contract announcements.

What would disappoint: Government Operations growth staying near 4%; net margins flat or dipping near 10%; a downward revision to fiscal 2027 guidance; commercial organic revenue declining again; or any signal that the Navy program is facing budget reprioritization. The stock would re-rate toward the bear scenario quickly.

Forward Valuation (from supplied research, current price applied):

Metric	Value	vs Sector Median	Assessment
Forward P/E	~30x	20.9x (45% premium)	Premium persisted but narrowed
PEG	1.82 (ChartMill); 10.94 (VCP)	n/a	Divergent inputs; treat with caution
EV/EBITDA (fwd)	~22x	12.4x (78% premium)	Expensive on EBITDA basis
Beta	Not provided in data	n/a	Trefis notes low volatility (Vol 12M 45%)

The beta figure is absent from the supplied data. Trefis characterizes BWXT as having low stock price volatility, which fits a monopoly defense contractor with a sovereign customer, but I cannot present a verified beta.

12. KEY BUSINESS DRIVERS

Driver 1: Government Operations revenue growth

Why it matters: This is 70% of revenue and the load-bearing pillar of the thesis. Without Government Operations growth, BWXT is a slow defensive compounder with cyclical bolted on.

Current level: Q1 2026 Government Operations revenue of \$577.9M, up only 4% year over year.

Bull threshold: Double-digit year-over-year growth, which AskTraders identifies as the analyst bar.

Bear threshold: Sustained growth below 5% for two quarters, which would signal Navy program pacing issues.

Next data point: Q3 2026 earnings on November 2, 2026.

Driver 2: Commercial Operations revenue growth

Why it matters: This is the growth engine and the source of the re-rating case. It converts the advanced nuclear narrative into reported revenue.

Current level: Q1 2026 Commercial Operations revenue of \$283.6M, up 121% year over year from \$128.3M.

Bull threshold: Organic revenue growth recovering alongside acquisition-driven growth; medical segment sustaining above \$100M annualized.

Bear threshold: Negative organic commercial revenue, which Simply Wall St flagged as a concern.

Next data point: Q3 2026 earnings plus any Kozloduy or AP1000 milestone announcements.

Driver 3: Backlog conversion and bookings

Why it matters: Backlog provides revenue visibility but only converts to profit if margins hold. Bookings replenish the future.

Current level: \$8.65B backlog, roughly 2.6x annual revenue; fiscal 2025 bookings up 51% to \$5.36B.

Bull threshold: Backlog above 2.5x revenue with bookings exceeding annual revenue each quarter.

Bear threshold: Two consecutive booking declines or backlog falling below 2.0x revenue.

Next data point: Each quarterly earnings release.

Driver 4: Segment EBITDA margins

Why it matters: This determines whether revenue growth translates to free cash flow and validates the premium multiple.

Current level: Government Operations 19.2%, Commercial Operations 14.2% in Q3 2025; consolidated net margin flat near 10.3%.

Bull threshold: Government Operations above 20%, consolidated net margin above 11%.

Bear threshold: Government Operations below 15%, net margin below 9%.

Next data point: Q3 2026 earnings.

Driver 5: Microreactor and advanced nuclear milestones

Why it matters: The Janus selection and TRISO fuel business are the option value that justifies the premium over slower defense primes.

Current level: Army selected BANR microreactor for Fort Campbell in August 2026; Kozloduy AP1000 contract December 2025; medical unit above \$100M.

Bull threshold: Janus deployment timetable holds and TRISO fuel orders scale.

Bear threshold: Janus cancellation, delay, or budget cut; failure to convert design awards to construction awards.

Next data point: Investor Day September 29, 2026 and quarterly disclosures.

13. PROXY TRACKERS & LEADING INDICATORS

Proxy	Ticker/Symbol	Relationship	Signal
iShares U.S. Aerospace & Defense ETF	ITA	Leads defense complex sentiment	Bullish if ITA holds above its 200-day moving average
Cameco Corp	CCJ	Correlates with commercial nuclear nuclear sentiment	Bullish if CCJ trends higher and confirms BWXT
Industrial Select Sector SPDR	XLI	Broad industrial risk appetite and defense sensitivity	Bullish if XLI stabilizes as yields fall; bearish if XLI declines
10-Year U.S. Treasury Yield	TNX / US10Y	Inversely pressures premium-multiple environment	Bullish if US10Y stays below 4.0%; bearish if US10Y rises

Monitoring rule: If ITA breaks below its 200-day moving average and the 10-year yield simultaneously prints above 4.75%, re-evaluate the BWXT thesis within five trading days, regardless of any positive company-specific news. If CCJ rallies while BWXT fails to follow, treat it as a warning on the commercial nuclear leg. If the 10-year yield falls below 4.0% and XLI strengthens, the valuation pressure recedes and the entry target can be revisited.

EXIT TRIGGERS

If the recommendation shifts from HOLD to BUY at the \$124 entry target, the following triggers would dictate exit or re-review:

- **Loss of Navy sole-source status or a major contract dispute:** Sell immediately. The entire moat rests on this position. Any credible signal that the Navy is qualifying an alternative supplier constitutes a thesis break.
- **Government Operations EBITDA margin below 15% for two consecutive quarters:** Sell or re-review. This would indicate pricing pressure or execution failure in the anchor segment.
- **Consolidated net margin below 9% for two consecutive quarters:** Re-review to sell. This would mean revenue growth is not converting to profit, breaking the compounding case.
- **Dividend cut:** Sell. A cut would signal a capital-allocation shift or a cash-flow crisis inconsistent with the preservation profile.
- **Forward P/E above 35x without a corresponding earnings guidance raise:** Trim. This would reintroduce the valuation risk that justified the initial HOLD.
- **Convertible notes converting at more than 2% annual dilution:** Re-review. Dilution accelerates the return deterioration.
- **Backlog falling below 2.0x revenue or two consecutive years of declining bookings:** Re-review to sell. The revenue visibility cushion would be eroding.
- **Break below \$101 (the near-term bear support) on higher volume with weakening backlog commentary:** Reassess the entire thesis. This price would signal the market pricing a structural funding

problem, not a multiple wobble.

- **A nuclear safety or environmental incident at any BWXT facility:** Sell on the first credible report. Tail risk is not worth holding through.
- **10-year Treasury yield above 5.0%:** Trim or exit. At that level, the risk-free alternative begins to rival the equity return expectation.

FINAL RECOMMENDATION

RECOMMENDATION: HOLD / WATCHLIST

BWX Technologies is an exceptional business trading at a fair price. A wealth-preservation mandate does not buy fair prices for exceptional businesses; it buys discounts to fair value and demands a margin of safety. The company passes the bear-case test with a positive 2% ten-year return, passes the base-case test with 8.9%, and passes the solvency test with adequate free cash flow coverage. It fails the margin-of-safety test at \$140.51, where the price sits above the \$138 fair-value midpoint and offers a negative 1.8% cushion.

The stock has already de-rated 35% from its May highs, which supports patience rather than urgency. The forward multiple has compressed to its five-year average. Another leg down toward \$124 would restore the asymmetry the mandate requires: a forward multiple near 27x on a monopoly compounder with \$8.65B in backlog and rising free cash flow. That entry would justify a standard position.

For an investor who already holds BWXT, the instruction is to hold and monitor the triggers above. For an investor evaluating entry, the instruction is to place a limit order at \$124 and wait. The 4% savings account remains the appropriate alternative while waiting, not a forced entry into a fairly valued position. Target entry: \$124.00 / €109.00. Target price within two years: \$160 / €141, reflecting a 30x multiple on fiscal 2027 earnings near \$5.30.

ANALYST NOTES

Key Assumptions:

- Fiscal 2026 adjusted EPS midpoint of \$4.62 per company guidance of \$4.55 to \$4.70.
- Long-term earnings growth of 9% in the base case, consistent with the 8% to 10% consensus CAGR cited in the research.
- Terminal multiple of 28x in the base case, matching the five-year average forward multiple.
- Dividend yield approximated at 0.8%, flagged as an external estimate absent from the supplied data.
- Terminal bear multiple of 22x and bull multiple of 32x.
- Shares outstanding of 91.4M per the StockTitan reference.

Limitations:

- Dividend data was absent from the supplied research; the dividend analysis relies on an externally sourced estimate and is marked accordingly.
- Management names, compensation, insider ownership, and a five-year capital allocation history were not provided.

- Geographic revenue split was not provided.
- Beta and short interest were not provided.
- Market cap, revenue, and valuation figures conflict across sources; I reconciled toward the Trefis and SEC 10-K figures and the authoritative \$140.51 price.
- The convertible notes due 2030 terms were not disclosed in the supplied data.
- Several valuation multiple snapshots reference higher price bases (September and May 2026); I recomputed forward multiples at the current \$140.51.

Confidence Level: MEDIUM — The moat quality and free cash flow trajectory are well documented and support a high-conviction view of business quality. Confidence is reduced by the absence of dividend, management, dilution, and convertible-note specifics, which are material to a preservation decision. The HOLD recommendation reflects not uncertainty about the business but discipline about the price.

Report prepared for Moschovakis Capital. This analysis is for informational purposes only.

CONTINUE THE RESEARCH

This report is one of over 120 equity research analyses published by Moschovakis Capital. Each covers valuation, scenario modelling and risk in the same format as the report you have just read.

Full equity research archive

Latest published research

Enquiries and coverage requests

moschovakiscapital.com

IMPORTANT DISCLOSURES

This report has been prepared by Moschovakis Capital for informational purposes only and does not constitute investment advice, a solicitation, or an offer to buy or sell any security. The information contained herein is based on sources believed to be reliable but is not guaranteed as to accuracy or completeness. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Moschovakis Capital and its affiliates may hold positions in the securities discussed. This document is confidential and intended solely for the recipient. Any reproduction or distribution without prior written consent is prohibited.